Acute exacerbation of pain in irritable bowel syndrome: Efficacy of phloroglucinol/trimethylphloroglucinol - A randomized, double-blind, placebo-controlled study

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 9, 2007, Pages 1115-1123

  Chassany, O ^a,i   Bonaz, B ^b   Bruley Des Varannes, S ^c   Bueno, L ^d   Cargill, G ^e   Coffin, B ^f   Ducrotte P ^g   Grange V ^h  

^a SAINT LOUIS HOSPITAL   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c HÔTEL DIEU   (France)

^d CNRS   (France)

^e Serv d'Explorations Fonctionnelles   (France)

^f HÔPITAL LOUIS MOURIER   (France)

^g HÔPITAL CHARLES NICOLLE   (France)

^h Cephalon France   (France)

ⁱ ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SPASFON;

ABDOMINAL PAIN; ADULT; ANALGESIA; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FLATULENCE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PAIN MEASUREMENT; PHLOROGLUCINOL; TREATMENT OUTCOME;

EID: 34247100202     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03296.x     Document Type: Article

References (34)

1. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45(Suppl. 2): II43-7.
2. Amouretti M, Le Pen C, Gaudin AF, et al. Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQL). Gastroenterol Clin Biol 2006; 30: 241-6.
3. Bouin M, Plourde V, Boivin M, et al. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002; 122: 1771-7.
4. Kumar D, Wingate D. Irritable bowel syndrome: a paroxysmal motor disorder. Lancet 1986; 1: 620-1.
5. Kellow JE, Phillips SF, Miller LJ, Zinsmeister AR. Dysmotility of the small intestine in irritable bowel syndrome. Gut 1988; 29: 1236-43.
6. Gorard DA, Libby GW, Farthing MJ. Ambulatory small intestinal motility in 'diarrhoea' predominant irritable bowel syndrome. Gut 1994; 35: 203-10.
7. Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology 1987; 92: 1885-93.
8. Spiller RC. Disturbances in large bowel motility. Baillieres Best Pract Res Clin Gastroenterol 1999; 13: 397-413.
9. Delvaux M. Alterations of sensori-motor functions of the digestive tract in the pathophysiology of irritable bowel syndrome. Best Pract Res Clin Gastroenterol 2004; 18: 747-71.
10. Louvel D, Delvaux M, Staumont G, et al. Intracolonic injection of glycerol: a model for abdominal pain in irritable bowel syndrome? Gastroenterology 1996; 110: 351-61.
11. Corazziari E, Bytzer P, Delvaux M, et al. Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2003; 18: 569-80.
12. Committee for Proprietary Medicinal Products (CPMP). Points to Consider On the Evaluation Of Medicinal Products For The Treatment Of Irritable Bowel Syndrome. CPMP/EWP/785/97, http://www.emea.eu.int/pdfs/human/ewp/ 078597en.pdf (accessed 27 February 2007).
13. Spiller RC. Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials. Am J Med 1999; 107: 91-7S.
14. Lipman R, Covi L. Outpatient treatment of neurotic depression: medication and group psychotherapy. In: Spitzer RL, Klein DL eds. Evaluation of the Psychological Therapies. Baltimore, MD: John Hopkins University Press, 1976: 178-218.
15. Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001; 48: 272-82.
16. Hahn B, Watson M, Yan S, Gunput D, Heuijerjans J. Irritable bowel syndrome symptom patterns: frequency, duration, and severity. Dig Dis Sci 1998; 43: 2715-8.
17. Tillisch K, Labus JS, Naliboff BD, et al. Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome. Am J Gastroenterol 2005; 100: 896-904.
18. Camilleri M. Management of the irritable bowel syndrome. Gastroenterology 2001; 120: 652-68.
19. Irvine E, Whitehead W, Chey W, et al., for Design of Treatment Trials Committee. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006; 130: 1538-51.
20. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15: 355-61.
21. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000; 133: 136-47.
22. Tack J, Fried M, Houghton LA, Spicak J, Fisher G. Systematic review: the efficacy of treatments for irritable bowel syndrome - a European perspective. Aliment Pharmacol Ther 2006; 24: 183-205.
23. Lesbros-Pantoflickova D, Michetti P, Fried M, Beglinger C, Blum AL. Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20: 1253-69.
24. Chassany O, Le-Jeunne P, Duracinsky M, Schwalm MS, Mathieu M. Discrepancies between patient-reported outcomes and clinician-reported outcomes in chronic venous disease, irritable bowel syndrome, and peripheral arterial occlusive disease. Value Health 2006; 9: 39-46.
25. Bardhan KD, Bodemer G, Geldof H, et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2000; 14: 23-34.
26. Pitz M, Cheang M, Bernstein CN. Defining the predictors of the placebo response in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 237-47.
27. Patel SM, Stason WB, Legedza A, et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil 2005; 17: 332-40.
28. Tack J, Müller-Lissner S, Bytzer P, et al. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 2005; 54: 1707-13.
29. Bueno L, Fioramonti J, Delvaux M, Frexinos J. Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroenterology 1997; 112: 1714-43.
30. Bommelaer G, Poynard T, Le Pen C, et al. Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria. Gastroenterol Clin Biol 2004; 28: 554-61.
31. Dapoigny M, Bellanger J, Bonaz B, et al. Irritable bowel syndrome in France: a common, debilitating and costly disorder. Eur J Gastroenterol Hepatol 2004; 16: 995-1001.
32. Drossman DA. Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome? Am J Med 1999; 107: 41S-50S.
33. Camilleri M. Ten secrets for development of drugs for functional gastrointestinal diseases. Gastroenterology 2000; 118: 653.
34. Longstreth G, Hawkey C, Mayer E, et al. Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials. Aliment Pharmacol Ther 2001; 15: 959-64.